Daiichi Jitsugyo Co (8059) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
4 Feb, 2026Executive summary
Achieved record-high profits at all levels in Q3 FY2025 despite a slight decline in sales year-over-year.
Net sales for the nine months ended December 31, 2025, were ¥160,272 million, a slight decrease of 0.3% year-over-year.
Operating income rose 9.1% to ¥10,863 million, and ordinary income increased 13.3% to ¥11,579 million compared to the same period last year.
Profit attributable to owners of parent grew 14.7% year-over-year to ¥8,323 million.
Significant profit growth driven by Healthcare, Aviation & Social Infrastructure segments, and gains from investment securities sales.
Financial highlights
Net sales decreased by 504 million yen YoY to 160.272 billion yen.
Operating income rose by 903 million yen YoY to 10.863 billion yen.
Ordinary income increased by 1.355 billion yen YoY to 11.579 billion yen.
Gross profit increased to ¥29,142 million from ¥27,593 million year-over-year.
Basic earnings per share for the nine months was ¥260.77, up from ¥228.72 year-over-year.
Outlook and guidance
FY2025 forecasts were upwardly revised; net sales forecast at 225 billion yen, operating income at 13.2 billion yen, and profit attributable to owners of parent at 9.6 billion yen.
Full-year net sales forecast is ¥225,000 million, a 1.5% increase year-over-year.
Basic earnings per share for the full year is expected to be ¥300.77.
Progress rates toward full-year forecasts: net sales 71.2%, operating income 82.3%, ordinary income 85.8%, profit attributable to owners of parent 86.7%.
Latest events from Daiichi Jitsugyo Co
- Record Q2 sales and profits led to upward revisions in full-year forecasts and dividends.8059
Q2 20267 Nov 2025 - Record-high sales and profit, improved equity ratio, and strong full-year outlook.8059
Q2 20259 Sep 2025 - Record Q3 sales and profits, stock split, and strong growth across all segments.8059
Q3 20259 Sep 2025 - Record sales and profits, strong overseas growth, and a conservative outlook for next year.8059
Q4 20259 Sep 2025 - Record Q1 sales and profits driven by Healthcare and Automobile, but outlook is slightly cautious.8059
Q1 20269 Sep 2025 - Strong sales and profit growth, with robust outlook and improved equity ratio.8059
Q1 20259 Sep 2025